Can MRI reveal if enzyme therapy protects hearts in fabry disease?
NCT ID NCT02956954
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study followed 26 people with Anderson-Fabry disease, some taking the enzyme replacement drug Replagal® and some not, to see how their hearts changed over two years. Researchers used special MRI scans to measure heart tissue relaxation time, which may indicate early damage. The goal was to find a better way to monitor whether treatment is protecting the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDERSON-FABRY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rouen University Hospital
Rouen, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Agalsidase alpha (Replagal®)
What this could lead to
If successful, this could show that Replagal® improves heart structure and function in Fabry disease, offering a way to monitor treatment effectiveness with MRI.
What could go wrong
This is a small, observational study with only 26 patients, so results may not apply to everyone. It does not test a new treatment, only tracks existing therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.